News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Email Alerts Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go Advanced Search Keywords Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard Mar 21, 2011 Insmed Regains NASDAQ Compliance Mar 21, 2011 Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication Mar 10, 2011 Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results Mar 3, 2011 Insmed Announces European Medicines Agency Acceptance of Its Pediatric Investigation Plan for ARIKACE™ in the Cystic Fibrosis Pseudomonas Indication Mar 2, 2011 One-for-10 Reverse Stock Split of Insmed Common Stock Becomes Effective Mar 1, 2011 Insmed Shareholders Approve Conversion of Series B Conditional Convertible Preferred Stock and Reverse Stock Split Feb 24, 2011 Insmed to Participate on Phase III and Beyond Panel at 2011 RBC Capital Markets Healthcare Conference Feb 23, 2011 Insmed to Host Fourth Quarter and 2010 Year-End Earnings Conference Call Dec 16, 2010 NASDAQ Grants Insmed Incorporated 180-Day Extension to Regain Compliance with Minimum Bid Price Rule Dec 2, 2010 Insmed Incorporated and Transave, Inc. Announce Business Combination Show 5102550100 per page«1…38394041424344…69» Stay In The Loop Want to stay up to date on our news, events, and filings? Set up your email alerts. Sign Up View the latest Insmed Investor Presentation Download